In the present study, we performed a longitudinal multicentre study to investigate how genetic variants of PNPLA3, TM6SF2, MBOAT7 and GCKR affect the risk of developing severe liver disease, cardiovascular disease (CVD) and overall mortality in a cohort of well‐characterized patients with NAFLD with extensive follow‐up. This evidence concerns the gene TM6SF2 and liver disorder.